Publication:

Cosmetovigilance studies to assess the safety of cosmetic therapy in hair segments and skin non-laser

Background Cosmetic procedures, especially non-laser skin treatments and hair rejuvenation therapies, are increasingly popular, yet ADRs remain a significant safety concern, particularly in patients with comorbidities. This study employed a cosmetovigilance-based approach to evaluate the safety, efficacy, and long-term outcomes of commonly used cosmetic therapies.

Methods A retrospective interventional cohort study was conducted at Kosmoderma Ltd. involving 410 patients aged 18–60 years who received cosmetic treatments between April and July 2024. Hair rejuvenation therapies included QR678, platelet-rich plasma (PRP), and growth factor concentrate (GFC), while non-laser skin procedures comprised chemical peels and facials. A minimum sample size of 199 was calculated to ensure statistical reliability. ADRs were identified, monitored, and categorized using structured data collection forms. Statistical analyses were performed using Chi-square tests and Spearman correlation to assess associations and risk factors.

Results Of the 410 patients evaluated, females constituted 78% of the study population, with equal representation of hair and non-laser skin treatments. A statistically significant association was observed between the type of hair therapy and ADR occurrence (χ²=6.89, p=0.032). No significant association was found between non-laser skin treatments and ADRs. Comorbidities, particularly diabetes mellitus, showed a strong association with both the incidence (p<0.001) and severity (p=0.021) of ADRs.

Conclusions Hair rejuvenation therapies and patient comorbidities significantly influence ADR occurrence. Integration of cosmetovigilance practices and active involvement of clinical pharmacists can enhance patient safety, support informed decision-making, and optimize cosmetic treatment protocols.